Abstract Number: PB0048
Meeting: ISTH 2022 Congress
Theme: COVID and Coagulation » COVID and Coagulation, Clinical
Background: The severe clinical conditions and fatal outcomes resulting from SARS-CoV-2 infection have been associated with increased inflammatory and hypercoagulability processes, where an interplay between different comorbidities and genetic factors would be directly involved in the poor prognosis.
Aims: To study the association of different genetic variants, clinical variables and biological markers involved in inflammation and coagulation with the survival outcome of COVID-19.
Methods: 204 unvaccinated COVID-19 confirmed patients were grouped and compared according to their survival outcome. Inflammatory and hemostatic variables measured upon hospital admission, different clinical variables and the genotypic distributions of the genetic variants Factor II20210A (II20210A), Factor V Leiden (FVL), Fibrinogen Gamma 10034C>T (FGG10034C/T), Factor XI7872C>T (FXI7872C/T) and rs11385942 were compared between patients that either died (n=63) or survived (n=141). Differences between continuous variables were analyzed by either a t-test or a U-Mann Whitney test and differences in genotypic distributions were studied by a Chi-square test. Cut off values were set for continuous variables significantly associated with a fatal outcome and their Odds Ratios (OR) of association were calculated through univariate logistic regression.
Results: The group of patients who died were significantly older, had a higher BMI index and presented with a lower platelet count, lower lymphocytes levels, higher levels of leukocytes and neutrophils, a higher neutrophils/lymphocytes ratio and higher levels of D-dimer, Ferritin and LDH than survivors. No differences were observed in the genotypic distributions of the genetic variants studied between both groups.
Conclusion(s): In agreement with previous studies, age, obesity, and the levels of different hematological and plasmatic markers upon hospital admission would be useful predictors of a fatal outcome in COVID-19 patients. Despite the typical exacerbation of inflammation/coagulation in severe COVID-19, no association was found between the carriage of any of the proinflammatory/prothrombotic genetic variants studied and a higher risk of dying.
To cite this abstract in AMA style:
Aranda F, Perés S, Cunto E, Chediack V, Peralta M, Bocassi A, Valero J, Svencionis M, Chamorro J, Rubilar T, Crespi Abril A, de Larrañaga G. Genetic variants and biological markers of coagulation and inflammation to predict the survival outcome upon SARS-CoV-2 infection in a cohort of patients from the first wave of COVID-19 in Argentina [abstract]. https://abstracts.isth.org/abstract/genetic-variants-and-biological-markers-of-coagulation-and-inflammation-to-predict-the-survival-outcome-upon-sars-cov-2-infection-in-a-cohort-of-patients-from-the-first-wave-of-covid-19-in-argentina/. Accessed March 21, 2024.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/genetic-variants-and-biological-markers-of-coagulation-and-inflammation-to-predict-the-survival-outcome-upon-sars-cov-2-infection-in-a-cohort-of-patients-from-the-first-wave-of-covid-19-in-argentina/